Danny Issa

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2558853/publications.pdf

Version: 2024-02-01

34 18,843 24 32 papers citations h-index g-index

34 34 34 17891 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology, 2018, 67, 328-357.	7.3	4,738
2	The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology, 2012, 55, 2005-2023.	7.3	2,935
3	Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis. New England Journal of Medicine, 2010, 362, 1675-1685.	27.0	2,718
4	Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet, The, 2015, 385, 956-965.	13.7	1,840
5	MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology, 2020, 158, 1999-2014.e1.	1.3	1,840
6	AGA technical review on nonalcoholic fatty liver disease. Gastroenterology, 2002, 123, 1705-1725.	1.3	961
7	Effect of Vitamin E or Metformin for Treatment of Nonalcoholic Fatty Liver Disease in Children and Adolescents. JAMA - Journal of the American Medical Association, 2011, 305, 1659.	7.4	926
8	Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transplantation, 2001, 7, 363-373.	2.4	390
9	A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer. Journal of Hepatology, 2016, 65, 579-588.	3.7	371
10	Management of NAFLD: a stage-based approach. Nature Reviews Gastroenterology and Hepatology, 2016, 13, 196-205.	17.8	287
11	Epidemiology and Natural History of Nonalcoholic Fatty Liver Disease. Seminars in Liver Disease, 2015, 35, 221-235.	3.6	278
12	No Significant Effects of Ethyl-Eicosapentanoic Acid on Histologic Features of Nonalcoholic Steatohepatitis in a Phase 2 Trial. Gastroenterology, 2014, 147, 377-384.e1.	1.3	260
13	Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD). Journal of Hepatology, 2012, 57, 384-391.	3.7	233
14	Activation of transmembrane bile acid receptor TGR5 stimulates insulin secretion in pancreatic \hat{l}^2 cells. Biochemical and Biophysical Research Communications, 2012, 427, 600-605.	2.1	172
15	The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis. Hepatology, 2018, 67, 1284-1302.	7.3	134
16	Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science. Hepatology, 2018, 67, 2001-2012.	7.3	125
17	Long-term Outcomes in Patients Undergoing Liver Transplantation for Nonalcoholic Steatohepatitis-Related Cirrhosis. Transplantation, 2017, 101, 1867-1874.	1.0	112
18	Nonalcoholic Steatohepatitis is the Most Rapidly Increasing Indication for Liver Transplantation in Young Adults in the United States. Journal of Clinical Gastroenterology, 2018, 52, 339-346.	2.2	96

#	Article	IF	CITATIONS
19	Similar Risk of Cardiopulmonary Adverse Events Between Propofol and Traditional Anesthesia for Gastrointestinal Endoscopy: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology, 2017, 15, 194-206.	4.4	95
20	Coronary artery disease in decompensated patients undergoing liver transplantation evaluation. Liver Transplantation, 2018, 24, 333-342.	2.4	78
21	Nonalcoholic Steatohepatitis (NASH) and Hepatic Fibrosis: Emerging Therapies. Annual Review of Pharmacology and Toxicology, 2018, 58, 649-662.	9.4	56
22	Future therapy for nonâ€alcoholic fatty liver disease. Liver International, 2018, 38, 56-63.	3.9	42
23	Vascular Disease in Patients with Nonalcoholic Fatty Liver Disease. Seminars in Thrombosis and Hemostasis, 2015, 41, 488-493.	2.7	29
24	Small Dense Lowâ€Density Lipoprotein Cholesterol Predicts Cardiovascular Events in Liver Transplant Recipients. Hepatology, 2019, 70, 98-107.	7.3	29
25	Translating scientific discovery: the need for preclinical models of nonalcoholic steatohepatitis. Hepatology International, 2018, 12, 6-16.	4.2	24
26	Treatment options for nonalcoholic steatohepatitis - a safety evaluation. Expert Opinion on Drug Safety, 2017, 16, 903-913.	2.4	23
27	Nonalcoholic fatty liver disease and hepatocellular carcinoma: new insights on presentation and natural history. Hepatobiliary Surgery and Nutrition, 2017, 6, 401-403.	1.5	15
28	Longitudinal studies can identify distinct inflammatory cytokines associated with the inhibition or progression of liver cancer. Liver International, 2020, 40, 468-472.	3.9	13
29	Differential fuel utilization in liver transplant recipients and its relationship with nonâ€alcoholic fatty liver disease. Liver International, 2022, 42, 1401-1409.	3.9	8
30	Non-alcoholic fatty liver disease: a pandemic disease with multisystem burden. Hepatobiliary Surgery and Nutrition, 2018, 7, 389-391.	1.5	7
31	Acute pancreatitis secondary to the use of the anabolic steroid trenbolone acetate. Clinical Toxicology, 2019, 57, 60-62.	1.9	5
32	Spontaneous transmural perforation in eosinophilic esophagitis: RARE case presentation and role of esophageal stenting. Journal of Surgical Case Reports, 2019, 2019, rjz190.	0.4	3
33	Lesser curve approach to gastric peroral endoscopic myotomy: aÂcase series. VideoGIE, 2019, 4, 532-534.	0.7	0
34	Jaccoud's Arthropathy and Jaundice in a Young Woman. Clinical Gastroenterology and Hepatology, 2020, 18, A34-A35.	4.4	0